Vmbook Online ordering
Siga Technologies Inc
SIGA Technologies Inc. (SIGA) is a publicly traded biotechnology company based in the United States, specializing in the development of antiviral drugs. The company is primarily known for the development and commercialization of TPOXX (tecovirimat), the first oral antiviral drug approved for the treatment of smallpox in adults and children.
Here are some general details about SIGA Technologies Inc:
1. Stock Exchange: SIGA is listed on the NASDAQ stock exchange under the ticker symbol "SIGA."
2. Headquarters: The company is headquartered at 1185 Avenue of the Americas, 33rd floor, New York, NY 10036, United States.
3. Founded: SIGA Technologies Inc. was established in 2002.
4. Executive Leadership: The company's leadership team includes:
- Phillip S. Gomez, Ph.D., President and Chief Executive Officer
- Dennis J. Hynes, Ph.D., Executive Vice President, Chief Scientific Officer
- Andrew J. Reckles, Executive Vice President, Chief Financial Officer
- Jeffrey L. C designation="font-weight: 400;">Van Treeck, Vice President, General Counsel & Secretary
5. Market Capitalization (as of May 2023): Approximately $3 billion, according to Yahoo Finance.
6. Products and Pipeline: SIGA Technologies Inc.'s primary focus is on the development of antiviral drugs for the treatment of various diseases, including smallpox, monkeypox, and other orthopoxviruses.
7. Collaborations: SIGA has collaborated with various organizations, institutes, and government agencies, including the Biomedical Advanced Research and Development Authority (BARDA), the Department of Defense, and the National Institute of Allergy and Infectious Diseases (NIAID) for the development, testing, and manufacturing of its drug candidates.
8. Financial Performance: Financial reports and filings for SIGA Technologies Inc., including quarterly and annual reports, are available on the Securities and Exchange Commission (SEC) website and the company's investor relations page.
For up-to-date and detailed information about SIGA Technologies Inc., it is recommended to visit their investor relations page (